Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/FJC.0000000000001358 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic potential and pharmacological mechanisms of Traditional Chinese Medicine in gout treatment.
Acta Pharmacol Sin
January 2025
Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Gout is a systemic metabolic disorder caused by elevated uric acid (UA) levels, affecting over 1% of the population. The most common complication of gout is gouty arthritis (GA), characterized by swelling, pain or tenderness in peripheral joints or bursae, which can lead to the formation of tophi. At present, western medicines like colchicine, febuxostat and allopurinol are the primary treatment strategy to alleviate pain and prevent flare-ups in patients with GA, but they have significant side effects and increased mortality risks.
View Article and Find Full Text PDFOutcomes of acute pericarditis with an inflammatory phenotype.
Int J Cardiol
January 2025
Cardiology and Cardiothoracic Department, University Hospital "Santa Maria della Misericordia" (ASUFC) Udine, Italy.
Background: Patients with pericarditis may show elevation of C-reactive protein (CRP) and pericardial effusion at presentation. There are limited data on the prognostic implications of this inflammatory phenotype.
Objectives: Aim of the present study is to evaluate the outcome of the inflammatory phenotype in a cohort of patients with acute pericarditis.
Advancement in the Treatment of Recurrent Pericarditis: Exploring Innovative Therapeutic Options.
S D Med
October 2024
Department of Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
Acute pericarditis, the predominant pericardial disease, often lacks a clear etiology, with 15-30% of patients experiencing recurrence, rising to 20-50% in those with prior relapses. Autoimmune mechanisms significantly contribute to recurrence, with interleukin-1 identified as a pivotal inflammatory mediator. While NSAIDs, colchicine, and steroids remain staples for acute cases, the spotlight in recurrent pericarditis management has shifted toward immunosuppressive medications.
View Article and Find Full Text PDFComment on "colchicine to prevent cardiovascular death after an acute myocardial infarction".
J Formos Med Assoc
January 2025
Department of Cardiovascular medicine, Yunnan First People's Hospital, Affiliated Hospital of Kunming University of Science and Technology, Yunnan, China. Electronic address:
Weekly Journal Scan: no CLEAR evidence of cardiovascular benefits of colchicine after acute myocardial infarction.
Eur Heart J
January 2025
Department of Cardiovascular and Pulmonary Sciences, Catholic University School of Medicine, Largo F. Vito 1, Rome 00168, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!